Source comparison
Tesamorelin Dosage Guide: Clinical Comparison Across GHRH Analogs
Understanding how tesamorelin compares to other growth hormone secretagogues clarifies why dosing precision varies by compound class and mechanism. | GHRH Analog | Standard Dose | Administration Frequency | Mechanism of Action | Half-Life | Primary Research Ap
This comparison does not assign a generated winner or score.
- Understanding how tesamorelin compares to other growth hormone secretagogues clarifies why dosing precision varies by compound class and mechanism.
- | GHRH Analog | Standard Dose | Administration Frequency | Mechanism of Action | Half-Life | Primary Research Application | Bottom Line ||—|—|—|—|—|—|| Tesamorelin | 2mg subcutaneous | Once daily (morning fasted) | GHRH receptor agonist. Triggers pulsatile GH release from pituitary | 26–38 minutes | Visceral adipose tissue reduction in HIV-associated lipodystrophy; metabolic syndrome research | Most selective for VAT reduction with pulsatile GH release pattern; requires daily dosing due to short half-life || Sermorelin | 200–300mcg subcutaneous | Once daily (bedtime) | GHRH analog (1–29 fragment). Stimulates endogenous GH secretion | ~10–20 minutes | Age-related GH decline studies; sleep quality research | Shortest half-life of GHRH analogs; physiologically identical to natural GHRH but more cost-sensitive due to frequent dosing || CJC-1295 (no DAC) | 100–200mcg subcutaneous | 1–3 times daily | GHRH analog with extended half-life via amino acid substitutions | ~30 minutes without DAC m
- Tesamorelin's 2mg daily dose is significantly higher in absolute micrograms than sermorelin or CJC-1295, but potency per microgram varies by receptor binding affinity and plasma stability. The therapeutic effect depends on area-under-the-curve GH release, not peak dose—tesamorelin's structural modifications enhance resistance to enzymatic degradation, allowing a longer effective window despite the short half-life.